Evidence mapPaperPMID 24909237Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2014

Enhancing human islet transplantation by localized release of trophic factors from PLG scaffolds.

K A Hlavaty, R F Gibly, X Zhang, C B Rives, J G Graham, W L Lowe, X Luo, L D Shea

Open access · bronzeAbstract read
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. An engineered macroencapsulation membrane releasing FTY720 to precondition pancreatic islet transplantation.Journal of biomedical materials research. Part B, Applied biomaterials · 2018
    Article
  17. Article
  18. Immune Tolerance for Autoimmune Disease and Cell Transplantation.Annual review of biomedical engineering · 2016
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

K A HlavatyThe Institute for BioNanotechnology in Medicine (IBNAM), Northwestern University, Chicago, IL; Department of Biomedical Engineering, Northwestern University, Evanston, IL.
R F Gibly
X Zhang
C B Rives
J G Graham
W L Lowe
X Luo
L D Shea
Northwestern University · US

Funding

Biotechnology Predoctoral Training ProgramT32GM008449 · NORTHWESTERN UNIVERSITY · 1993 to 2005
$1.5M
NIBIB NIH HHS R01 EB009910NIBIB NIH HHS R01EB009910NIDDK NIH HHS F30 DK084649NIGMS NIH HHS T32 GM008449
6 · The paper itself

Abstract

Islet transplantation represents a potential cure for type 1 diabetes, yet the clinical approach of intrahepatic delivery is limited by the microenvironment. Microporous scaffolds enable extrahepatic transplantation, and the microenvironment can be designed to enhance islet engraftment and function. We investigated localized trophic factor delivery in a xenogeneic human islet to mouse model of islet transplantation. Double emulsion microspheres containing exendin-4 (Ex4) or insulin-like growth factor-1 (IGF-1) were incorporated into a layered scaffold design consisting of porous outer layers for islet transplantation and a center layer for sustained factor release. Protein encapsulation and release were dependent on both the polymer concentration and the identity of the protein. Proteins retained bioactivity upon release from scaffolds in vitro. A minimal human islet mass transplanted on Ex4-releasing scaffolds demonstrated significant improvement and prolongation of graft function relative to blank scaffolds carrying no protein, and the release profile significantly impacted the duration over which the graft functioned. Ex4-releasing scaffolds enabled better glycemic control in animals subjected to an intraperitoneal glucose tolerance test. Scaffolds releasing IGF-1 lowered blood glucose levels, yet the reduction was insufficient to achieve euglycemia. Ex4-delivering scaffolds provide an extrahepatic transplantation site for modulating the islet microenvironment to enhance islet function posttransplant.

Indexed as

Islets of Langerhans TransplantationAnimalsBlood GlucoseDiabetes Mellitus, ExperimentalExenatideFemaleGlucose Tolerance TestGraft SurvivalHumansInsulin-Like Growth Factor IMaleMiceMice, Inbred NODMicrospheresMiddle AgedPeptidesBlood GlucoseExenatideInsulin-Like Growth Factor IPeptidesPolyglactin 910VenomsBioengineeringislet xenotransplantationregenerative medicinetype 1 diabetes mellitus

Identifiers

PMID24909237
PMCPMC4232190
OpenAlexW1601582416

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.